Castle Biosciences Reports Third Quarter 2026 Results

Castle Biosciences reported Q3 2026 revenue of $102.9 million, up 24% year over year, with TissueCypher test report volume rising 47%; it raised full-year revenue guidance to $385–395 million from $365–375 million. Q3 adjusted EBITDA increased to $12.7 million from $9.2 million, while net loss widened to $4.1 million from $0.5 million. For the first nine months, adjusted EBITDA fell to $20.0 million from $32.5 million and operating cash flow declined to $12.8 million from $37.4 million; the company maintained its expectation for positive adjusted EBITDA in Q4 2026 and full years 2026 and 2027.

Analysis

The mix, not the headline growth rate, is the investable signal: TissueCypher is taking the lead while DecisionDx-Melanoma is comparatively mature. If TissueCypher adoption converts into repeat ordering and reimbursement, it could improve the durability of growth; if not, the portfolio’s headline expansion may mask limited momentum in the established dermatology franchise. The clinical studies support a commercial narrative, but publication and clinician preference changes do not establish payer coverage or realized pricing.

The raised revenue range implies roughly $95–105 million of Q4 revenue after the first nine months, so the new outlook does not itself require a sharp sequential acceleration. Near-term attention should be on the call’s detail on TissueCypher reimbursement, average selling prices, and capacity—not just report volume. Q3 adjusted EBITDA improved, but nine-month adjusted EBITDA and operating cash flow were below last year; receivables, prepaid costs, and capital spending warrant monitoring. The cash balance reduces financing risk, while the GAAP loss is materially affected by equity-security marks and should not be read as a clean proxy for core operating deterioration.

Over 1–3 months, confirmation of volume-to-revenue conversion and the Q4 profitability target is the key catalyst. Over 6–18 months, payer decisions and repeat clinical adoption determine whether TissueCypher and newer tests broaden the growth base. The Scottsdale expansion may support capacity, but also raises the bar for utilization. SciBase’s collaboration has a plausible pipeline read-through, but the disclosed order is not evidence of material near-term revenue for SciBase.

Key Decisions for Investors

• CSTL: Maintain a constructive but measured stance; avoid chasing the guidance raise before the conference call clarifies reimbursement, pricing, and Q4 volume assumptions. Consider initiating or adding only on weakness if management substantiates durable TissueCypher conversion.
• For the next 1–3 months, track TissueCypher reports versus revenue/adjusted revenue, accounts-receivable growth and collections, and confirmation of positive Q4 adjusted EBITDA. A volume increase without revenue conversion, or a cut to the profitability outlook, would falsify the constructive thesis.
• Do not underwrite the newer dermatology tests on publication evidence alone. Watch payer coverage and sustained report volumes; continued softness in DecisionDx-SCC or MyPath alongside flat melanoma volumes would weaken the diversification case.
• Treat SCIB as a watch item rather than a trade on this disclosure: the collaboration may support future clinical progress, but the small disclosed order does not establish meaningful earnings impact. Reassess only with evidence of study progress, commercial adoption, or material contract economics.